Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0600

-6.3%

Nov 10 3:45 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	12/31/2013 9:03:38 AM
	Read Replies (1) of 13111

Melanoma Treatment Achieves Positive Interim Results. The U-T San Diego (12/30, Fikes) reports OncoSec Medica said it “achieved positive interim results in a Phase 2 trial of its melanoma treatment.” The company, which develops immune therapies for cancer, disclosed the results Dec. 16 at the Advances in Cancer Immunotherapy meeting at UC San Francisco. The paper says “the trial adds to evidence presented this year that cancer immunotherapy is becoming more effective.” According to the paper, of 21 patients evaluated 180 days after treatment, “eight experienced tumor reductions of 30 percent or more. The disease stabilized in another two patients for at least three months, bringing clinical benefit.” The company’s treatment, OMS-I100, “adds a gene in the tumor that makes an immune-stimulating molecule, interleukin-12.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next